RegenxbioRGNX
RGNX
About: Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Employees: 344
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
25% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 51
19% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 26
2% more funds holding
Funds holding: 182 [Q2] → 186 (+4) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
4.02% less ownership
Funds ownership: 97.4% [Q2] → 93.38% (-4.02%) [Q3]
14% less capital invested
Capital invested by funds: $561M [Q2] → $484M (-$77.1M) [Q3]
77% less call options, than puts
Call options by funds: $1.5M | Put options by funds: $6.66M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
191%
upside
Avg. target
$35
362%
upside
High target
$52
587%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Luca Issi 17% 1-year accuracy 10 / 60 met price target | 296%upside $30 | Outperform Reiterated | 21 Jan 2025 |
HC Wainwright & Co. Yi Chen 38% 1-year accuracy 59 / 156 met price target | 376%upside $36 | Buy Reiterated | 15 Jan 2025 |
Chardan Capital Daniil Gataulin 29% 1-year accuracy 10 / 34 met price target | 587%upside $52 | Buy Maintained | 20 Nov 2024 |
Morgan Stanley Judah Frommer 33% 1-year accuracy 3 / 9 met price target | 191%upside $22 | Overweight Assumed | 15 Nov 2024 |
Financial journalist opinion
Based on 4 articles about RGNX published over the past 30 days
Neutral
Seeking Alpha
5 days ago
Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026
Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025. Partnership established with Nippon Shinyaku to develop RGX-121 and RGX-111 for the treatment of patients with MPS II and MPS I respectively. Data from both the ASCENT and ATMOSPHERE pivotal studies, using ABBV-RGX-314 for the treatment of patients with Wet Age-Related Macular Degeneration, expected in 2026.
Neutral
Seeking Alpha
6 days ago
Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again
Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie, targets wet AMD with global regulatory submissions expected in H1 2026; RGX-121 has a rolling BLA submission expected to complete in Q1 2025. Financially, RGNX has a market cap of $344mn and a cash balance of $279mn, bolstered by a recent $110mn upfront fee from Nippon Shinyaku.
Neutral
PRNewsWire
1 week ago
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing Nippon Shinyaku to lead commercialization of first potential gene therapies for Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis I (MPS I) in U.S. and Asia REGENXBIO retains rights to RGX-121 Priority Review Voucher (PRV) with potential accelerated approval expected in 2025; rolling BLA submission underway ROCKVILLE, Md. , Jan. 14, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd.
Neutral
PRNewsWire
1 week ago
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO will plan the Phase 3 clinical program of investigational ABBV-RGX-314 in diabetic retinopathy (DR) NORTH CHICAGO, Ill. and ROCKVILLE, Md.
Neutral
PRNewsWire
1 month ago
Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range.
Neutral
PRNewsWire
2 months ago
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026 Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above with first patient dosed Phase I/II data show RGX-202 recipients exceeding external natural history and established benchmarks for clinical outcomes Functional improvements seen in all patients treated with dose level 1 and dose level 2 at 12 and 9 months respectively New biomarker data confirms consistent robust expression of differentiated RGX-202 microdystrophin in the muscle Favorable safety profile observed at both dose levels; no serious adverse events or AEs of special interest Webcast to be held at 8:00 a.m. today ROCKVILLE, Md.
Neutral
PRNewsWire
2 months ago
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
- Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne ROCKVILLE, Md.
Neutral
Seeking Alpha
2 months ago
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.41 per share a year ago.
Neutral
PRNewsWire
2 months ago
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for Duchenne Muscular Dystrophy; pivotal trial initiation and first functional data expected this month BLA submission for RGX-121 initiated and expected to complete in Q1 2025 Positive Phase II data support bilateral administration of subretinal ABBV-RGX-314; data consistent with that from multiple previous studies demonstrating favorable safety and efficacy profile End-of-Phase II meeting for ABBV-RGX-314 in diabetic retinopathy accelerated to Q4 2024 to support global pivotal program initiation in H1 2025 Conference call today at 4:30 p.m. ET ROCKVILLE, Md.
Charts implemented using Lightweight Charts™